Investig Clin Urol.  2017 Jan;58(1):42-47. 10.4111/icu.2017.58.1.42.

Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment

• Kim A
• Lee KS
• Kim TB
• Kim HJ
• Yoo ES
• Yun JH
• Kim DY
• Jung SG
• Lee JT
• Kim JM
• Oh CK
• Shin JH
• Jeon SH
• Lee SH
• Han CH
• Lee DH
• Cho HJ
• Choo MS

• KMID: 2365095
• DOI: http://doi.org/10.4111/icu.2017.58.1.42

Abstract

PURPOSE
To identify incidence and risk factors of recurrence after discontinuation of successful antimuscarinic therapy in patients with overactive bladder (OAB).
MATERIALS AND METHODS
This was a prospective, multicenter trial. Patients who had antimuscarinic agents for more than 12 weeks and showed successful response were enrolled. Successful response was defined as answering 'benefit' for patient perception of treatment benefit and answer lesser than 3 points in patient's perception of bladder condition (PPBC). The enrolled patients discontinued the antimuscarinics, and we evaluated their recurrence with PPBC and OAB symptom score (OABSS) at 1, 3, 6, and 12 months. Primary purpose was to identify the recurrence rate and secondary purpose was to reveal risk factors.
RESULTS
Four hundred forty-one patients enrolled and 371 patients completed 6-month follow-up. The enrolled patients showed 1.6 points in PPBC, 2.9 points in OABSS and 1.4 points in IPSS (quality of life) which represented successful response after using antimuscarinics. The cumulative rates of recurrence were 25.6%, 42.3%, and 52.2% at 1, 3, 6 months, respectively. Among 177 patients who did not show recurrence at 6 months, 41 patients were followed up and 4 patients of the 41 patients (9.7%) showed recurrence at 12 months. On univariate and multivariate analyses of recurrence, OAB wet was the risk factor for recurrence after 6 months of discontinuation.
CONCLUSIONS
Discontinuation of antimuscarinic therapy after successful treatment resulted in high recurrence rate with time and OAB wet was the independent risk factor for recurrence.

Keyword

Antimuscarinic treatment; Overactive bladder; Recurrence

MeSH Terms

Follow-Up Studies
Humans
Incidence*
Multicenter Studies as Topic
Multivariate Analysis
Muscarinic Antagonists
Prospective Studies
Recurrence*
Risk Factors*
Urinary Bladder
Urinary Bladder, Overactive*
Muscarinic Antagonists

Figure

• 

  Fig. 1 Cumulative rates and new cases of overactive bladder symptom recurrence after discontinuation of antimuscarinic treatment.

Reference

1. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009; 28:287.

2. Wein AJ. Diagnosis and treatment of the overactive bladder. Urology. 2003; 62:5 Suppl 2. 20–27.

3. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol. 2002; 41:588–595.

4. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004; 93:303–310.

5. Choo MS, Song C, Kim JH, Choi JB, Lee JY, Chung BS, et al. Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial. J Urol. 2005; 174:201–204.

6. Kim TH, Lee KS. Persistence and compliance with medication management in the treatment of overactive bladder. Investig Clin Urol. 2016; 57:84–93.

7. Kim TH, Choo MS, Kim YJ, Koh H, Lee KS. Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome. Qual Life Res. 2016; 25:2021–2029.

8. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011; 108:1132–1138.

9. Wehrberger C, Madersbacher S, Jungwirth S, Fischer P, Tragl KH. Lower urinary tract symptoms and urinary incontinence in a geriatric cohort - a population-based analysis. BJU Int. 2012; 110:1516–1521.

10. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003; 326:841–844.

11. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol. 2005; 48:5–26.

12. Lee YS, Choo MS, Lee JY, Oh SJ, Lee KS. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial. Int J Clin Pract. 2011; 65:997–1004.

13. Wen JG, Li JS, Wang ZM, Huang CX, Shang XP, Su ZQ, et al. The prevalence and risk factors of OAB in middle-aged and old people in China. Neurourol Urodyn. 2014; 33:387–391.

14. Ricci JA, Baggish JS, Hunt TL, Stewart WF, Wein A, Herzog AR, et al. Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther. 2001; 23:1245–1259.

15. Irwin DE, Milsom I, Kopp Z, Abrams P. EPIC Study Group. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol. 2008; 53:1029–1037.

16. Song HJ, Han MA, Kang HC, Park KS, Kim KS, Kim MK, et al. Impact of lower urinary tract symptoms and depression on health-related quality of life in older adults. Int Neurourol J. 2012; 16:132–138.

17. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61:37–49.

18. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs. 2004; 64:1643–1656.

19. Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol. 2002; 4:Suppl 4. S7–S18.

20. Drake M, Gillespie J, Hedlund P, Harvey I, Lagou M, Andersson KE. Muscarinic stimulation of the rat isolated whole bladder: pathophysiological models of detrusor overactivity. Auton Autacoid Pharmacol. 2006; 26:261–266.

21. Andersson KE, Holmquist F, Fovaeus M, Hedlund H, Sundler R. Muscarinic receptor stimulation of phosphoinositide hydrolysis in the human isolated urinary bladder. J Urol. 1991; 146:1156–1159.

22. Andersson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology. 2003; 62:5 Suppl 2. 3–10.

23. Kuo HC, Liu HT, Guan Z, Tyagi P, Chancellor MB. Promise of urinary nerve growth factor for assessment of overactive bladder syndrome. Low Urin Tract Symptoms. 2011; 3:2–9.

24. Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int. 2009; 103:1668–1672.

25. Griffiths D, Tadic SD, Schaefer W, Resnick NM. Cerebral control of the bladder in normal and urge-incontinent women. Neuroimage. 2007; 37:1–7.

26. de Groat WC. A neurologic basis for the overactive bladder. Urology. 1997; 50:6A Suppl. 36–52.

27. Brading AF, Turner WH. The unstable bladder: towards a common mechanism. Br J Urol. 1994; 73:3–8.

28. Drake MJ, Mills IW, Gillespie JI. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet. 2001; 358:401–403.

29. Andersson KE. Detrusor myocyte activity and afferent signaling. Neurourol Urodyn. 2010; 29:97–106.